HK1217343A1 - Fusion immunomodulatory proteins and methods for making same - Google Patents

Fusion immunomodulatory proteins and methods for making same

Info

Publication number
HK1217343A1
HK1217343A1 HK16105342.6A HK16105342A HK1217343A1 HK 1217343 A1 HK1217343 A1 HK 1217343A1 HK 16105342 A HK16105342 A HK 16105342A HK 1217343 A1 HK1217343 A1 HK 1217343A1
Authority
HK
Hong Kong
Prior art keywords
methods
making same
immunomodulatory proteins
fusion
fusion immunomodulatory
Prior art date
Application number
HK16105342.6A
Other languages
Chinese (zh)
Inventor
高溫答帕 納夾拉耶
梅麗娜 索雷斯 瑪利亞
薩斯特里 卡答納斯
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of HK1217343A1 publication Critical patent/HK1217343A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HK16105342.6A 2013-03-12 2016-05-10 Fusion immunomodulatory proteins and methods for making same HK1217343A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361777016P 2013-03-12 2013-03-12
PCT/US2014/022404 WO2014164427A1 (en) 2013-03-12 2014-03-10 Fusion immunomodulatory proteins and methods for making same

Publications (1)

Publication Number Publication Date
HK1217343A1 true HK1217343A1 (en) 2017-01-06

Family

ID=51658871

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105342.6A HK1217343A1 (en) 2013-03-12 2016-05-10 Fusion immunomodulatory proteins and methods for making same

Country Status (16)

Country Link
US (3) US9988456B2 (en)
EP (1) EP2970512B1 (en)
JP (2) JP6605444B2 (en)
CN (1) CN105121474B9 (en)
AU (2) AU2014249405C1 (en)
BR (1) BR112015022733B1 (en)
CA (2) CA3081073C (en)
DK (1) DK2970512T3 (en)
ES (1) ES2704411T3 (en)
HK (1) HK1217343A1 (en)
MY (1) MY186864A (en)
NZ (1) NZ711445A (en)
PL (1) PL2970512T3 (en)
PT (1) PT2970512T (en)
RU (2) RU2662991C2 (en)
WO (1) WO2014164427A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2938182T3 (en) 2012-04-30 2023-04-05 Biocon Ltd Targeting/immunomodulatory fusion proteins and methods of preparation thereof
JP6605444B2 (en) * 2013-03-12 2019-11-13 バイオコン・リミテッド Fusion immunoregulatory protein and production method thereof
JP2016528295A (en) 2013-08-22 2016-09-15 アクセルロン ファーマ， インコーポレイテッド TGF-beta receptor type II mutant and use thereof
CN104403004B (en) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 The preparation and use of antibody interferon heterodimer
WO2016135041A1 (en) * 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
BR112018000768A2 (en) 2015-07-13 2018-09-25 Cytomx Therapeutics Inc anti-pd-1 antibodies, activatable anti-pd-1 antibodies and methods of use
EP4218792A1 (en) 2015-08-04 2023-08-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
WO2017037634A1 (en) * 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-β-receptor ectodomain fusion molecules and uses thereof
UA126549C2 (en) 2015-10-01 2022-11-02 Хіт Байолоджикс, Інк. Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
MX2018007089A (en) 2015-12-14 2019-01-30 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof.
WO2017134592A1 (en) * 2016-02-03 2017-08-10 Biocon Limited Anti-cd20/immunomodulatory fusion proteins and methods for making same
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2018064190A1 (en) * 2016-09-27 2018-04-05 Epicentrx, Inc. Immunomodulatory fusion proteins
EP3518953A4 (en) 2016-09-29 2020-10-28 Aebi Ltd. Therapeutic multi-targeting constructs and uses thereof
CN110234345A (en) 2017-02-27 2019-09-13 沙塔克实验室有限公司 The method for making and using the chimeric protein based on extracellular domain
CN110381974A (en) 2017-02-27 2019-10-25 沙塔克实验室有限公司 Chimeric protein based on CSF1R
AU2018224852A1 (en) 2017-02-27 2019-07-11 Shattuck Labs, Inc. VSIG8-based chimeric proteins
WO2018158727A1 (en) 2017-03-02 2018-09-07 National Research Council Of Canada Tgf-β-receptor ectodomain fusion molecules and uses thereof
KR102635723B1 (en) * 2017-05-04 2024-02-08 악셀레론 파마 인코포레이티드 TGF-beta receptor type II fusion protein and uses thereof
CN110050000B (en) * 2017-05-12 2022-07-26 苏州盛迪亚生物医药有限公司 Fusion protein containing TGF-beta receptor and medical application thereof
CN111432828A (en) * 2017-05-26 2020-07-17 约翰霍普金斯大学 Multifunctional antibody-ligand capture agents to modulate immune tolerance
CN111032092A (en) * 2017-06-30 2020-04-17 韩国科学技术院 Conjugates of VEGF-GRAB proteins and drugs and uses thereof
MX2020002268A (en) * 2017-09-02 2021-01-08 Abbvie Inc Anti-egfr antibody drug conjugates (adc) and uses thereof.
WO2019046858A1 (en) * 2017-09-02 2019-03-07 Abbvie Inc. Anti-egfr antibody drug conjugates (adc) and uses thereof
CA3077223A1 (en) 2017-09-27 2019-04-04 Epicentrx, Inc. Immunomodulatory fusion proteins
EA202091710A1 (en) 2018-03-09 2021-02-16 Агенус Инк. ANTIBODIES AGAINST CD73 AND METHODS OF THEIR USE
US11945844B2 (en) 2018-05-06 2024-04-02 Amai Proteins Ltd. Taste and flavor-modifier proteins
AU2019271065A1 (en) * 2018-05-15 2020-11-05 Merck Patent Gmbh Dosing regimens for targeted TGF-B inhibition for use in treating cancer in treatment naive subjects
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
EP3878461A4 (en) 2018-11-09 2022-08-17 Jiangsu Hengrui Medicine Co., Ltd. TGF-ß RECEPTOR FUSION PROTEIN PHARMACEUTICAL COMPOSITION AND USE THEREOF
CN110563851B (en) * 2019-08-20 2020-06-12 启辰生生物科技(珠海)有限公司 Fusion protein with immunoregulation function, pharmaceutical composition, cell and application
CN110734498A (en) * 2019-10-15 2020-01-31 上海科棋药业科技有限公司 fusion protein for relieving immunosuppression and application thereof
CN110964118A (en) * 2019-11-27 2020-04-07 中国药科大学 Bispecific fusion antibody and application thereof in tumor immunotherapy
BR112022021785A2 (en) * 2020-04-28 2022-12-06 Sinocelltech Ltd TGFBR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE, TGFBR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE FUSION PROTEIN AND ANTI-EGFR ANTIBODY AND ANTI-TUMOR USE OF FUSION PROTEIN
CN111690070A (en) * 2020-05-13 2020-09-22 深圳市众循精准医学研究院 sPD-1-Fc-sTGF beta RII fusion protein and application thereof
WO2022057061A1 (en) * 2020-09-16 2022-03-24 Suzhou Neologics Bioscience Co., Ltd. Pd-l1 antibodies, fusion proteins, and uses thereof
WO2022132202A1 (en) * 2020-12-15 2022-06-23 Bicara Therapeutics Inc. Combination therapy for the treatment of cancer
WO2022132201A2 (en) * 2020-12-15 2022-06-23 Bicara Therapeutics Inc. Pharmaceutical formulations for fusion proteins
UY39610A (en) 2021-01-20 2022-08-31 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
AU2022339953A1 (en) * 2021-09-03 2024-02-29 Novarock Biotherapeutics, Ltd. BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGFβ AND USES THEREOF

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG60017A3 (en) 1988-09-28 1993-06-15 Lilly Co Eli Method for reducing the heterogeneity of monoclonal antibodies
RU2120475C1 (en) * 1990-05-17 1998-10-20 Макс-Планк-Гезельшафт Цур Фердерунг дер Виссеншафтен е.ф. Method of synthesis of polypeptide, hybrid dna (variants), fusion protein (variants)
WO1998033914A1 (en) 1997-01-31 1998-08-06 University Of Rochester Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
UA83791C2 (en) * 2001-04-13 2008-08-26 Байоджен Айдек Ма Инк. Antibody to vla-1, pharmaceutical composition, containing thereof, and use of them for treatment individual having immunological disorder, mediated by vla-1
EP2037892B1 (en) 2006-06-19 2015-03-18 Asklepios Biopharmaceutical, Inc. Modified factor viii and factor ix genes and vectors for gene therapy
JP2010512770A (en) 2006-12-22 2010-04-30 アレス トレーディング ソシエテ アノニム Analysis method for analyzing C-terminal cleavage
EP2031064A1 (en) * 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Method for increasing protein titres
MX349306B (en) 2007-09-21 2017-07-19 Univ California Targeted interferon demonstrates potent apoptotic and anti-tumor activities.
WO2009114110A1 (en) 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
JP5304275B2 (en) 2009-01-29 2013-10-02 Ｊｎｃ株式会社 Codon optimized nucleic acid encoding apocrytin-II and methods of use thereof
WO2011102845A1 (en) * 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
WO2011109789A2 (en) * 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
WO2012147053A1 (en) * 2011-04-29 2012-11-01 Biocon Research Limited A method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
WO2013004841A1 (en) * 2011-07-06 2013-01-10 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
US8604447B2 (en) 2011-07-27 2013-12-10 Kla-Tencor Corporation Solar metrology methods and apparatus
ES2938182T3 (en) * 2012-04-30 2023-04-05 Biocon Ltd Targeting/immunomodulatory fusion proteins and methods of preparation thereof
JP6605444B2 (en) * 2013-03-12 2019-11-13 バイオコン・リミテッド Fusion immunoregulatory protein and production method thereof
JP2018167875A (en) * 2017-03-30 2018-11-01 株式会社フジシール Container package and manufacturing method of container package

Also Published As

Publication number Publication date
US9988456B2 (en) 2018-06-05
AU2018202982B2 (en) 2019-08-22
AU2014249405A1 (en) 2015-10-29
AU2014249405B2 (en) 2018-02-01
US20200399379A1 (en) 2020-12-24
DK2970512T3 (en) 2019-01-14
US10766963B2 (en) 2020-09-08
JP2016512508A (en) 2016-04-28
CA3081073C (en) 2023-09-12
CA2902830C (en) 2023-09-19
RU2662991C2 (en) 2018-07-31
CN105121474A (en) 2015-12-02
PL2970512T3 (en) 2019-03-29
RU2018117558A3 (en) 2019-01-30
JP2019010111A (en) 2019-01-24
CA3081073A1 (en) 2014-10-09
AU2018202982A1 (en) 2018-05-17
AU2014249405C1 (en) 2018-08-16
CA2902830A1 (en) 2014-10-09
WO2014164427A1 (en) 2014-10-09
RU2018117558A (en) 2018-10-26
ES2704411T3 (en) 2019-03-18
MY186864A (en) 2021-08-26
US20160009807A1 (en) 2016-01-14
EP2970512A1 (en) 2016-01-20
CN105121474B (en) 2020-03-31
BR112015022733B1 (en) 2023-02-14
EP2970512A4 (en) 2016-11-09
NZ711445A (en) 2018-06-29
RU2015140608A (en) 2017-04-18
PT2970512T (en) 2019-01-17
EP2970512B1 (en) 2018-10-10
US20180251560A1 (en) 2018-09-06
CN105121474B9 (en) 2020-06-19
JP6605444B2 (en) 2019-11-13
BR112015022733A2 (en) 2017-10-31
RU2698975C2 (en) 2019-09-02

Similar Documents

Publication Publication Date Title
HK1217343A1 (en) Fusion immunomodulatory proteins and methods for making same
HK1251589A1 (en) Targeted/immunomodulatory fusion proteins and methods for making same
EP2968551A4 (en) Fusion proteins and methods thereof
IL240034A0 (en) Pd-l1 and pd-l2-based fusion proteins and uses thereof
HK1220466A1 (en) Apelin fusion proteins and uses thereof
EP2877854A4 (en) Fusion proteins and methods thereof
EP2943512A4 (en) Bovine fusion antibodies
HRP20190434T1 (en) Fusion protein
PL2986633T3 (en) Methods for the expression of peptides and proteins
HK1220903A1 (en) Cartilage-binding fusion proteins
PL2983704T3 (en) Fusion polypeptides and vaccines
EP2995313A4 (en) Placenta extracts and method for preparing same
EP2985347A4 (en) Method for detecting protein stability and uses thereof
GB201318840D0 (en) Method and device for protein preparation
EP2854356A4 (en) Method and device for multi-link fusion
HK1218422A1 (en) Fusion proteins and methods for identifying bromodomain inhibiting compounds
EP2986725A4 (en) Methods and materials for encapsulating proteins
EP3029071A4 (en) Saxatilin-fc fusion protein and use thereof
GB201308120D0 (en) Recombinant protein and method for its production
AU2013901331A0 (en) Fusion Proteins and Use Thereof
GB201301640D0 (en) Methods and peptides